Trastuzumab deruxtecan in patients with HER2-mutant metastatic non-small-cell lung cancer: primary results from the randomized, phase II DESTINY-Lung02 trial (vol 42, 10.1200/JCO-24-01883, 2024)

Author(s):: Goto, K.; Goto, Y.; Kubo, T.; Ninomiya, K.; Kim, S.W.; Planchard, D.; Ahn, M.J.; Smit, E.F.; Langen, A.J. de; Pérol, M.; Pons-Tostivint, E.; Novello, S.; Hayashi, H.; Shimizu, J.; Kim, D.W.; Kuo, C.H.; Yang, J.C.H.; Pereira, K.; Cheng, F.C.; Taguchi, A.; Cheng, Y.K.; Feng, W.Q.; Tsuchihashi, Z.; Jänne, P.A.

Published: 2024
Publication type: Article / Letter to editor

Date issued: 2024-10-20
Language: English
Is part of: Journal of Clinical Oncology (2024), Vol. 42, no. 30, p. 3635-3635
hdl: 1887/4213108
doi: 10.1200/JCO-24-01883
URL: https://ascopubs.org/doi/10.1200/JCO-24-01883